000597 Stock Overview
Engages in the chemical raw materials, chemical preparations, pharmaceutical, pharmaceutical engineering, biomedicine, and other businesses in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Northeast Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.13 |
| 52 Week High | CN¥6.69 |
| 52 Week Low | CN¥3.72 |
| Beta | 0.29 |
| 11 Month Change | 4.06% |
| 3 Month Change | 23.91% |
| 1 Year Change | -12.01% |
| 33 Year Change | 0.39% |
| 5 Year Change | 10.62% |
| Change since IPO | 13.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000597 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.1% | -1.5% | -2.1% |
| 1Y | -12.0% | -9.4% | 2.8% |
Return vs Industry: 000597 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 000597 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 000597 volatility | |
|---|---|
| 000597 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 000597 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000597's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 6,214 | Zhou Kai | www.nepharm.com.cn |
Northeast Pharmaceutical Group Co., Ltd. engages in the chemical raw materials, chemical preparations, pharmaceutical, pharmaceutical engineering, biomedicine, and other businesses in China. It offers vitamin products, including vitamin C, vitamin B1, vitamin B6, and levocarnitine series; anti-infection products, such as fosfomycin series, azithromycin series, berberine hydrochloride, chloramphenicol, and other products.; and reproductive system and sex hormone products comprising carprost, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. The company also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; essence and cannabis-containing series products, including morphine hydrochloride injection, pethidine hydrochloride injection, compound codeine phosphate syrup, morphine hydrochloride tablets, and oxycodone hydrochloride injection; anti-AIDS products comprising kedu/zidovudine tablets, efavirenz tablets, and other products; digestive system products, which include bacillus licheniformis, aluminum magnesium carbonate chewable tablets, and other products; and in vitro biological diagnostic reagent products, such as HIV, HBV, HCV, HPV, and TB molecular diagnostic reagents.
Northeast Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 000597 fundamental statistics | |
|---|---|
| Market cap | CN¥7.33b |
| Earnings (TTM) | CN¥346.65m |
| Revenue (TTM) | CN¥7.97b |
21.1x
P/E Ratio0.9x
P/S RatioIs 000597 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000597 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.97b |
| Cost of Revenue | CN¥5.36b |
| Gross Profit | CN¥2.61b |
| Other Expenses | CN¥2.27b |
| Earnings | CN¥346.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 32.80% |
| Net Profit Margin | 4.35% |
| Debt/Equity Ratio | 39.7% |
How did 000597 perform over the long term?
See historical performance and comparison